ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0886

Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study

Rachel Giblon1, Sara Achenbach2, Elena Myasoedova1, John Davis1, Vanessa Kronzer1 and Cynthia Crowson3, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, Rochester, MN, 3Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: Anxiety, depression, population studies, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Depression and anxiety are known to occur more commonly in patients with RA. For example, recent studies estimate a depression point-prevalence of 17% in patients with RA, compared to 5% in the general population. Newer treatments for RA have led to better outcomes, but it is unknown whether improved control of RA disease activity has also decreased depression and anxiety in patients with RA. We aimed to investigate trends in depression/anxiety incidence over 3 decades in a population-based cohort of patients with RA.

Methods: We identified incident RA cases (age >18 years, met 1987 ACR criteria in 1985-2014) in a geographically defined area. Patients were followed until death, migration or 12/31/2020. Depression and anxiety were defined using established ICD9/10 code sets and requiring at least 2 diagnosis codes 30 days apart. Patients with depression or anxiety prior to RA incidence date were excluded. Cox proportional hazards models compared trends in incidence of depression and anxiety by decade, adjusting for age and sex. Cumulative incidence of depression and anxiety adjusted for competing risk of death was calculated.

Results: The study included 1012 patients with RA (mean age 55.9 years; 68% female). There were 240, 343, and 429 cases in 1985-1994, 1995-2004 and 2005-2014, respectively. Depression and anxiety present at RA incidence both increased significantly (p< 0.001) over the 3 time periods (8%, 21%, 30% for depression and 5%, 8%, 17% for anxiety, respectively). During median follow-up of 10.6, 10.4 and 10.2 years per decade, depression developed in 80, 84, and 54 patients and anxiety developed in 37, 66, and 61 patients. There was no change in cumulative incidence of depression over time, but patients with incident RA in 2005–14 had markedly higher cumulative incidence of anxiety than patients diagnosed in earlier decades (Figure). Hazard ratios (HR) demonstrated a temporal increase in anxiety among patients with incident RA in 2005-2014 (HR: 2.98; 95% confidence interval (CI): 1.87-4.75) and patients with incident RA in 1995-2004 (HR: 1.77; 95% CI: 1.15-2.71) compared with incident RA in 1985-1994. Results did not change after additional adjustment for smoking status and obesity or highest ESR in the first year of RA. These trends were most pronounced in RF/CCP positive patients (data not shown).

Conclusion: In incident RA patients, the occurrence of depression did not improve over time while the occurrence of anxiety increased substantially over time, particularly in RF/CCP positive patients. These findings may indicate increased awareness and diagnosis of anxiety. Nevertheless, the lack of improvement in depression and anxiety, despite advances in RA treatment, warrants further attention.

Supporting image 1

Figure 1. Cumulative incidence of depression and anxiety in patients with RA by decade of RA incidence


Disclosures: R. Giblon, None; S. Achenbach, None; E. Myasoedova, None; J. Davis, Pfizer; V. Kronzer, None; C. Crowson, None.

To cite this abstract in AMA style:

Giblon R, Achenbach S, Myasoedova E, Davis J, Kronzer V, Crowson C. Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/incidence-of-depression-and-anxiety-in-rheumatoid-arthritis-patients-over-three-decades-a-population-based-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-of-depression-and-anxiety-in-rheumatoid-arthritis-patients-over-three-decades-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology